- Home
- CVKD vs APRE Comparison
CVKD vs APRE Comparison
Compare CVKD & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVKD | APRE |
|---|---|---|
| Founded | 2022 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 8.4M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CVKD | APRE |
|---|---|---|
| Price | $5.28 | $1.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $13.00 | $4.10 |
| AVG Volume (30 Days) | 48.7K | ★ 416.4K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.94 | 21.22 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.21 | $0.55 |
| 52 Week High | $17.50 | $2.22 |
Technical Indicators
Market Signals| Indicator | CVKD | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 48.68 | 62.82 |
| Support Level | $5.13 | $0.90 |
| Resistance Level | $8.87 | $0.98 |
| Average True Range (ATR) | 0.49 | 0.10 |
| MACD | 0.14 | 0.03 |
| Stochastic Oscillator | 64.56 | 68.02 |
Price Performance
Historical ComparisonAbout CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.